Lundbeck Revenue and Competitors

Chicago, IL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Lundbeck's estimated annual revenue is currently $1.4B per year.(i)
  • Lundbeck's estimated revenue per employee is $201,000

Employee Data

  • Lundbeck has 6869 Employees.(i)
  • Lundbeck grew their employee count by 4% last year.

Lundbeck's People

NameTitleEmail/Phone
1
VP MarketingReveal Email/Phone
2
VP, Global Strategic Marketing, PsychiatryReveal Email/Phone
3
Director GPS Data ManagementReveal Email/Phone
4
Director, Aggregate ReportsReveal Email/Phone
5
Executive Director, Mature Brands and Innovation FundReveal Email/Phone
6
Sr. Director Quality Operations North AmericaReveal Email/Phone
7
Senior DirectorReveal Email/Phone
8
Medical Director Lundbeck (Switzerland) LtdReveal Email/Phone
9
Senior Manager, Regulatory AffairsReveal Email/Phone
10
CNS Neuroscience Senior Product ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.1M6530%N/AN/A
#2
$75.6M3767%N/AN/A
#3
$23.9M11913%$35MN/A
#4
$12.7M63-3%N/AN/A
#5
$5.4M27-25%N/AN/A
#6
$6M30-35%N/AN/A
#7
$6.6M33-8%N/AN/A
#8
$13.5M67-3%N/AN/A
#9
$186.3M92719%N/AN/A
#10
$4.4M22-4%N/AN/A
Add Company

What Is Lundbeck?

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.\n\nAn estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.\n\nDespite the challenges, Lundbeck remains steadfast in our commitment to deliver innovation that patients need. We work tirelessly to advance neuroscience, develop new and innovative treatments, and support patient communities – all with the aim of restoring brain health and transforming the lives of the millions of people living with a brain disease. Not only does the burden of brain diseases demand action now, it also demands expertise and courage. We know that to get radically different results, we need to pursue radically different approaches.\n\nOur approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France, and Italy. \n\nFor additional information, we encourage you to visit our corporate site www.lundbeck.com. \n\nThe privacy statement and applicable disclaimer for this company page can be found here: www.lundbeck.com/global/linkedin

keywords:N/A

N/A

Total Funding

6869

Number of Employees

$1.4B

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lundbeck News

2022-04-17 - H. Lundbeck A/S (OTCMKTS:HLUYY) Upgraded to “Buy” by ...

H. Lundbeck A/S (OTCMKTS:HLUYY) Upgraded to “Buy” by Zacks Investment Research. Posted by admin on Apr 26th, 2022.

2022-03-22 - Lundbeck to Present New Data at AAN 2022 Adding to ...

In the United States, Lundbeck employs more than 1,000 people focused solely on accelerating therapies for brain disorders. With a special...

2022-03-22 - Lundbeck Languishing Without Clear Drivers

Lundbeck has been beating Street operating earnings expectations, but the core growth-driving drugs have had more mixed performances,...

2021-11-15 - Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention

Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention Mon, Nov 15, 2021 09:01 CET The HOPE study, a clinical phase II study, will assess the efficacy, safety, and tolerability of Lu AG09222 in migraine prevention. H. Lundbeck A/S (Lundbeck) anno ...

2021-11-15 - Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention

Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention Mon, Nov 15, 2021 09:01 CET The HOPE study, a clinical phase II study, will assess the efficacy, safety, and tolerability of Lu AG09222 in migraine prevention. H. Lundbeck A/S (Lundbeck) anno ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A72806%N/A
#2
$6952.6M183938%N/A
#3
$11490M2559110%N/A
#4
$12450M385121%$1.7B
#5
$28360M426648%N/A